# Pulmonology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Phillis Wheatley (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN015-SYN
- Date: 2026-02-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gideon Fairbanks-Mensah, MD
- Calendar frame: modern shifted

- Requested by: Abena Hartley-Okonkwo, MD

## Reason for consultation

Three months of winter wheeze, cough and breathlessness in a 19-year-old never-smoking woman, born in West Africa, who has been called frail and asthmatic since childhood but has never had lung function testing or treatment. Please confirm or refute asthma with spirometry before and after bronchodilator and FeNO, help exclude other chest disease, and advise on treatment, including preparation for a long sea journey she may make in the spring. **S**

## History

Miss Wheatley, 19, is seen at the request of Dr. Hartley-Okonkwo for three months of winter wheeze, cough and breathlessness, on a background of a weak chest since childhood that was called asthma but never tested. Symptoms come on three or four days a week, with waking about twice a month, and are brought on by cold wind, kitchen and fireplace smoke, and colds. She has never smoked, has never had an inhaler, and has never needed emergency care for her breathing. She may travel by sea in the spring. She was seen alone and gave her own consent. **S**

## Examination

| System | Finding |
|---|---|
| General | Slight and composed, speaking in full sentences; oxygen saturation 98 percent |
| Nose and throat | Nasal mucosa normal; no polyps |
| Respiratory | Faint expiratory wheeze on forced expiration; no crackles; no clubbing |
| Cardiovascular | Regular rhythm; no murmur |

BP 106/66 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 45.8 kg; BMI 19.8 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Hartley-Okonkwo's intake note and results: chest X-ray clear; blood eosinophils 0.38; interferon-gamma release assay negative; urine pregnancy test negative; Asthma Control Test 15. This morning, in our laboratory, with GLI Global race-neutral equations: FEV1 2.24 L (83 percent predicted) before and 2.57 L after albuterol 400 mcg (+330 mL, +15 percent); FEV1/FVC 0.72 before, below the lower limit of normal of 0.75, and 0.80 after; FeNO 38 ppb. Total IgE 165 IU/mL; specific IgE positive to house dust mite and negative to cat and mold. FEV1 before bronchodilator: 2.24 L; FEV1 after bronchodilator: 2.57 L; FEV1 percent predicted before bronchodilator: 83%; FEV1/FVC before bronchodilator: 0.72 (low); FEV1/FVC after bronchodilator: 0.8; FeNO: 38 [ppb] (high); Total IgE: 165 [IU]/mL (high); Asthma Control Test: 16. All results are synthetic.

## Assessment

1. **Asthma, confirmed, mild persistent, with type 2 inflammation** (J45.30). Question 1: this is asthma. The FEV1/FVC below the lower limit of normal that rises to normal after albuterol, with a 330 mL (15 percent) rise in FEV1, shows variable, reversible airflow obstruction. Tuberculosis infection is excluded by the negative interferon-gamma release assay, and the clear chest X-ray argues against bronchiectasis or scarring; nothing in her history suggests inducible laryngeal obstruction. Question 2: with race-neutral GLI Global equations her FEV1 is 83 percent of predicted; older race-based equations would have set a lower predicted value and could have made her obstruction look like none at all. Question 4: FeNO 38 ppb, blood eosinophils of 0.38 and sensitization to house dust mite show type 2 inflammation, which responds well to inhaled corticosteroid. Her most important triggers are cold air, smoke from cooking and fires, and colds; dust mite matters in the bedroom. **S**
2. **Wheeze, cough and breathlessness** (R06.2). Explained by asthma. **S**

## Recommendations

1. Question 3: GINA track 1, step 2: budesonide-formoterol 160/4.5 mcg, one inhalation as needed for symptoms and before going out in the cold, up to 12 a day; no albuterol-only reliever. This halves the risk of severe exacerbations compared with albuterol alone and suits her symptoms on several days a week.
2. Teach technique with a spacer and check it at every visit; review six weeks after starting and within a week of any exacerbation; step up to maintenance and reliever (step 3) if control is not reached or after an exacerbation, and step back down when she is well.
3. A written action plan with peak flow zones, and a two-week diary to set her personal best.
4. Triggers: ventilate the kitchen and avoid fireplace smoke; a scarf over the mouth in cold wind; mite-proof bedding covers.
5. Question 5: for the journey, two inhalers and the spacer, zones set from her personal best, a standby five-day course of prednisone with clear start rules for when care is far away, treatment for seasickness, an aired cabin away from smoke, and a printed summary; spirometry and FeNO again after her return.
6. Question 6: well-controlled asthma is safe in pregnancy and uncontrolled asthma is the main risk; budesonide is the inhaled steroid with the most reassuring pregnancy data, and her treatment should continue, not stop, if she becomes pregnant; plan a review before and during any pregnancy.
7. Vaccines: influenza and COVID-19 each season, and PCV20 once, as an adult with asthma.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Hartley-Okonkwo the same day. The results were explained to Miss Wheatley alone, in plain words, with a printed copy; she asked how the reference equations work and why it matters. She decides who else may receive this note. **S**

## Follow-up

Pulmonology review after the repeat spirometry on her return, or sooner if an exacerbation occurs or control is not reached; Dr. Hartley-Okonkwo continues primary care and shares the monitoring. **S**

## Guideline basis

- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023), American Thoracic Society
- Latent Tuberculosis Infection in Adults: Screening (2023), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- ACOG Practice Bulletin No. 90: Asthma in Pregnancy. Obstet Gynecol 2008;111(2 Pt 1):457-464 (PMID 18238988) (2008), American College of Obstetricians and Gynecologists
- Motion Sickness (CDC Yellow Book: Health Information for International Travel) (2026), Centers for Disease Control and Prevention
